Protective properties of a candidate C-terminal domain OspA vaccine for prevention of Lyme disease
Monica E. Embers(Tulane University), Raphael Simon(University of Maryland, Baltimore), Amanda C. Tardo(Tulane University), Donna Giordano-Schmidt(Pfizer (United States)), Romana Hochreiter(Valneva (Austria)), Andrea Fritzer(Valneva (Austria)), Isis Kanevsky(Pfizer (United States)), Alexey V. Gribenko(Pfizer (United States)), Danielle Baranova(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), Alexandre Esadze(Pfizer (United States)), Yekaterina Timofeyeva(Pfizer (United States)), Sabine Wellnitz(Pfizer (United States)), Ursula Bartuschka(Valneva (Austria)), Michelle Gaylord(Pfizer (United States)), Guy Singh(Pfizer (United States)), Yan Li(Pfizer (United States)), Sandra Jost(Valneva (Austria)), Jun Sun(Pfizer (United States)), Sirena Tran(Pfizer (United States)), Jill Dane(Pfizer (United States)), Jeong-Jin Park(Pfizer (United States)), Stefan Seidel(Valneva (Austria)), Nicole R. Hasenkampf(Tulane University), Urban Lundberg(Valneva (Austria)), Annaliesa S. Anderson(Pfizer (United States)), Andreas Meinke(Valneva (Austria))
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937